Abstract
Induction of tumor vascular normalization is a crucial measure to enhance immunotherapy efficacy. cGAS-STING pathway is vital for anti-tumor immunity, but its role in tumor vasculature is unclear. Herein, using preclinical liver cancer models in Cgas/Sting-deficient male mice, we report that the interdependence between tumor cGAS and host STING mediates vascular normalization and anti-tumor immune response. Mechanistically, TET2 mediated IL-2/STAT5A signaling epigenetically upregulates tumor cGAS expression and produces cGAMP. Subsequently, cGAMP is transported via LRRC8C channels to activate STING in endothelial cells, enhancing recruitment and transendothelial migration of lymphocytes. In vivo studies in male mice also reveal that administration of vitamin C, a promising anti-cancer agent, stimulates TET2 activity, induces tumor vascular normalization and enhances the efficacy of anti-PD-L1 therapy alone or in combination with IL-2. Our findings elucidate a crosstalk between tumor and vascular endothelial cells in the tumor immune microenvironment, providing strategies to enhance the efficacy of combinational immunotherapy for liver cancer.
Introduction: The Vascular Barrier in Liver Cancer
Immune checkpoint blockade (ICB), such as anti-PD-L1 therapy, has transformed oncology, yet its efficacy remains limited in many patients. In highly angiogenic malignancies like hepatocellular carcinoma (HCC), tumors often develop chaotic, leaky blood vessels. This dysfunctional vasculature creates a hypoxic environment that suppresses immune activity and physically impedes the infiltration of cytotoxic T cells.
While anti-angiogenic agents can temporarily "normalize" these vessels, the therapeutic window is brief. This study investigates the cGAS-STING pathway—a known driver of anti-tumor immunity—and its previously unrecognized role in stabilizing tumor vasculature through a unique cellular crosstalk.
A Division of Labor: The Tumor-Endothelial Crosstalk
A key finding of this research is the "division of labor" between cancer cells and the host's vascular system. While liver cancer cells often lack the STING protein, they do express cGAS. Conversely, the endothelial cells lining the tumor's blood vessels express STING.
The researchers discovered that tumor-derived cGAS acts as a sensor, producing the messenger molecule cGAMP. This cGAMP is then exported from the cancer cell via LRRC8C membrane channels and taken up by nearby endothelial cells. This activation of the STING pathway in the endothelium stabilizes blood vessels by increasing pericyte coverage and strengthening cell junctions, which significantly improves the ability of CD8+ T cells to enter the tumor.
Vitamin C: An Epigenetic Switch for Vessel Normalization
The cGAS gene is frequently silenced in liver cancer through DNA methylation. The enzyme TET2 is capable of removing these inhibitory methyl groups to reactivate the gene. Since Vitamin C is a biological cofactor that enhances TET2 activity, the researchers hypothesized that pharmacological doses could "turn on" the cGAS-STING loop.
Using mouse models and co-culture assays, they confirmed that Vitamin C stimulates TET2, leading to increased tumor cGAS expression and subsequent vessel normalization. This epigenetic intervention effectively "primes" the tumor microenvironment for immunotherapy.
Key Results: Dose-Dependent Tumor Suppression
The study demonstrated a clear dose-dependent relationship between cGAS expression and therapeutic outcomes. Higher levels of tumor cGAS correlated with increased pericyte coverage, enhanced CD8+ T cell infiltration, and significantly reduced tumor weight.
Furthermore, combining high-dose Vitamin C (4 g/kg) with anti-PD-L1 therapy resulted in complete tumor repression in mouse models after 28 days. This synergy was entirely dependent on the proposed pathway; knocking out tumor cGAS or host Sting abolished the benefits. Clinical validation in 103 human HCC samples further supported these findings, showing that high expression of the TET2-cGAS-LRRC8C-STING axis correlates with better patient survival and normalized vasculature.
Conclusion and Future Directions
This research provides a mechanistic foundation for a new combinational approach to liver cancer treatment. By using Vitamin C to epigenetically activate the tumor-endothelial cGAS-STING crosstalk, clinicians may be able to normalize tumor vasculature and overcome resistance to immunotherapy. The authors suggest that these findings warrant clinical trials combining high-dose intravenous Vitamin C with immune checkpoint inhibitors for HCC patients.
Summary updated